Literature DB >> 15537168

In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog.

Ferenc Lévai1, Erzsébet Fejér, Gábor Szeleczky, Anna Szabó, Tünde Eros-Takácsy, Félix Hajdu, Gyula Szebeni, István Szatmári, István Hermecz.   

Abstract

It is well established in the litrature, that selegiline is metabolised to its N-dealkylated metabolites, N-desmethylselegiline, methamphetamine and amphetamine. However, most studies on selegiline metabolism did not characterize the species differences in the formation of the metabolites. Therefore, in this study, we investigated the in vitro metabolism of selegiline in liver microsomes of different species. In addition, to the previously well-characterized metabolites, selegiline-N-oxide (selegiline-NO) was found to be formed as a metabolite of selegiline in rat liver microsomal preparation. The results of experiments with liver microsomes from other species indicated species differences in the rate and extent of formation of selegiline-NO. The dog and hamster liver microsomal preparations were the most active in terms of selegiline-NO production, whereas little selegiline was metabolized to its N-oxide in human liver microsomes. When selegiline-NO was incubated with rat liver microsomes, no metabolism occurred. When a short incubation time was applied in selegiline expriments no increase in the amount of selegiline-NO was detected. Accordingly, it was clear that selegiline was not metabolized to the N-dealkylated or N,N-bis-dealkylated compounds via selegiline-NO. Studies with different isoenzyme inhibitors indicated that the formation of selegiline-NO might be catalyzed at least partly by cytochrome P450 (CYP) 2D6 and CYP3A4. With the exception of hamster microsomes in the microsomal preparations in vitro, the formation of the R,S-stereoisomer of selegiline-NO was preferred.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15537168     DOI: 10.1007/BF03190594

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  24 in total

1.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

Authors:  D J Newton; R W Wang; A Y Lu
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

2.  Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl.

Authors:  M Valoti; F Fusi; M Frosini; F Pessina; K F Tipton; G P Sgaragli
Journal:  Eur J Pharmacol       Date:  2000-03-17       Impact factor: 4.432

3.  Metabolism of N,N-dialkylated amphetamines, including deprenyl, by CYP2D6 expressed in a human cell line.

Authors:  M V Bach; R T Coutts; G B Baker
Journal:  Xenobiotica       Date:  2000-03       Impact factor: 1.908

Review 4.  Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.

Authors:  I Mahmood
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

5.  Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.

Authors:  P Taavitsainen; M Anttila; L Nyman; H Karnani; J S Salonen; O Pelkonen
Journal:  Pharmacol Toxicol       Date:  2000-05

6.  CYP2D6 polymorphism is not crucial for the disposition of selegiline.

Authors:  H Scheinin; M Anttila; M L Dahl; H Karnani; L Nyman; P Taavitsainen; O Pelkonen; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1998-10       Impact factor: 6.875

7.  Inhibition of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolic activity of porcine FAD-containing monooxygenase by selective monoamine oxidase-B inhibitors.

Authors:  R F Wu; Y Ichikawa
Journal:  FEBS Lett       Date:  1995-01-23       Impact factor: 4.124

8.  Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man.

Authors:  M Katagi; M Tatsuno; H Tsutsumi; A Miki; T Kamata; H Nishioka; K Nakajima; M Nishikawa; H Tsuchihashi
Journal:  Xenobiotica       Date:  2002-09       Impact factor: 1.908

9.  Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6.

Authors:  J M Grace; M T Kinter; T L Macdonald
Journal:  Chem Res Toxicol       Date:  1994 May-Jun       Impact factor: 3.739

10.  Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Authors:  M Schachter; C D Marsden; J D Parkes; P Jenner; B Testa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

View more
  1 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.